Sign In
Buy VOR
$21.15
-0.650 (-2.98%)
At Close: Jul 31, 2026
Vor Bio to Participate in Upcoming Investor Conferences
08:00am, Monday, 06'th May 2024
CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming inves
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 03'rd May 2024
CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of May 1, 2024, the Compensation Comm
Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors
04:01pm, Thursday, 02'nd May 2024
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Fouad Namouni, M.D., to its Board of
Why You Shouldn't Bet Against Vor Biopharma (VOR) Stock
09:36am, Thursday, 04'th Apr 2024
Vor Biopharma (VOR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Vor Bio to Participate in Upcoming Investor Conferences
08:00am, Monday, 01'st Apr 2024
CAMBRIDGE, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming inv
The Penny Stock A-List: 7 High-Profile Companies on the Verge of Greatness
02:28pm, Thursday, 28'th Mar 2024
In most cases, investors should stay away from penny stocks. They're wild, they're unpredictable and they tend to lose their stakeholders money more so than they return.
Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
04:05pm, Wednesday, 20'th Mar 2024
CAMBRIDGE, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and full y
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Tuesday, 05'th Mar 2024
CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of March 1, 2024, the Compensation
Vor Bio to Participate in Upcoming Investor Conferences
08:00am, Monday, 04'th Mar 2024
CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming inv
Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
08:00am, Wednesday, 07'th Feb 2024
CAMBRIDGE, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host vi
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 02'nd Feb 2024
CAMBRIDGE, Mass., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of January 29, 2024, the Compensatio
Vor Bio (VOR) Up on Positive Update From AML Cell Therapy Study
09:26am, Friday, 19'th Jan 2024
Vor Bio (VOR) stock gains after dosing the first patient in its phase I/II study of novel cell therapy, VCAR33 (Allogenic), to treat AML. The company extends its cash runway into the second half of 20
Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update
04:01pm, Wednesday, 17'th Jan 2024
CAMBRIDGE, Mass., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, announced today it has dosed the first patient in VBP301, its Phase 1/2
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Thursday, 21'st Dec 2023
CAMBRIDGE, Mass., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of December 20, 2023, the Compensati
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 01'st Dec 2023
CAMBRIDGE, Mass., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of November 29, 2023 the Compensatio
